Table 3 In vitro susceptibilities of Candida parapsilosis complex isolates considered in this study
From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex
Antifungal agents | MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | % of isolates in the indicated category according to CLSIa | |||||
|---|---|---|---|---|---|---|---|---|---|
S | SDD | I | R | WT | Non-WT | ||||
Amphotericin B | ≤0.12–1 | 0.5 | 0.5 | - | - | - | - | 100 | 0 |
Flucytosine | ≤0.06–1 | ≤0.06 | 0.25 | - | - | - | - | 97 | 3 |
Fluconazole | ≤0.12–4 | 0.25 | 1 | 98.4 | 1.6 | - | 0 | - | - |
Itraconazole | ≤0.015–0.25 | 0.06 | 0.12 | - | - | - | - | 100 | 0 |
Voriconazole | ≤0.008–0.06 | ≤0.008 | 0.015 | 100 | 0 | - | 0 | - | - |
Posaconazole | ≤0.008–0.12 | 0.03 | 0.06 | - | - | - | - | 100 | - |
Caspofungin | 0.06–1 | 0.25 | 0.5 | 100 | - | 0 | 0 | - | - |
Anidulafungin | 0.12–2 | 0.5 | 2 | 100 | - | 0 | 0 | - | - |
Micafungin | 0.12–2 | 1 | 2 | 100 | - | 0 | 0 | - | - |